Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
perifosine+ temsirolimus · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| perifosine + temsirolimus | EXPERIMENTAL | This is a single arm, phase I study. Eligible patients will receive a loading dose of oral perifosine on the first day, followed by a maintenance dose starting on the second day until progression. Each patient is assigned to a group according to their body surface area (BSA). Temsirolimus will be combined with perifosine at four dose levels to determine the MTD for the combination therapy. Temsirolimus dosing will start on the same day as the perifosine load. |
| Name | Type | Description |
|---|---|---|
| perifosine + temsirolimus | DRUG | The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary. |
Inclusion Criteria: * Any solid tumor that has failed standard therapy * Patient must have evidence of tumor by CT, MRI, MIBG scan, serum markers, or tissue sampling. * Age ≤ 21 years (age ≤ 35 years for biopsy proven medulloblastoma or neuroblastoma) * Karnofsky/Lansky performance status ≥ 50% (Ka...
Perifosine is an investigational small molecule being developed by COSCIENS Biopharma Inc. (CSCI) for the treatment of various cancers, including gastrointestinal stromal tumors, colorectal cancer, renal cell carcinoma, chondrosarcomas, and other neoplasms. It is currently in Phase 1 clinical development.
Perifosine is an investigational oncology drug. Its specific molecular target has not been disclosed in available information. It is being studied for its potential effects in multiple cancer types, including kidney cancer and solid tumors.
Perifosine is being developed by COSCIENS Biopharma Inc., a biopharmaceutical company listed on the stock exchange under the ticker symbol CSCI. The company is conducting clinical trials to evaluate the drug's safety and efficacy in oncology indications.
Perifosine is in Phase 1 clinical development. It has completed several clinical trials, including Phase 1 and Phase 2 studies, but is not yet approved by regulatory authorities. The drug remains investigational and is being evaluated for safety and dosing.
Perifosine has been studied in several completed clinical trials. These include NCT00415064, a Phase 1 study combining perifosine with lenalidomide and dexamethasone for multiple myeloma; NCT00498966, a Phase 2 study for kidney cancer; NCT00776867, a Phase 1 study for pediatric solid tumors; and NCT01224730, a food effect and QTc study in advanced malignancies.
Perifosine is a distinct investigational drug with no known alternative names. It is being studied as a single agent and in combination with other therapies, such as lenalidomide and dexamethasone, but it is not the same as those drugs.